● TIER 3 — Information onlyGRADE BGLP-1 / incretins & amylin
Amycretin
Unimolecular GLP-1/amylin agonist. Research verification: Yes (TGA pending). 1 human study record(s) in the FitClinicMD studies database.
GOALS · Weight loss
FDA status
Phase 3 (Novo Nordisk); investigational.
Compounding (503A/503B)
Not compoundable.
DEA
Not controlled.
WADA (sport)
S0 Non-approved substances
Mechanism
Unimolecular GLP-1/amylin agonist.
Human evidence · 1
Peer-reviewed trial. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
Reference only. This page summarizes publicly available regulatory and research information about Amycretin. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.